Preclinical Candidate to Commercial Therapy
This evolution is in development. Curriculum details — items, duration, and hero materials — will be added as the class is finalized.
The founder's path from preclinical candidate to commercial therapy. IND strategy as a capital structure decision, CDMO selection and its downstream consequences, CMC development milestones as funding triggers, and the manufacturing scale-up gap that destroys biotech companies between Phase II and commercial launch.
This evolution is under development. Content will be available when the next cohort begins.